Indian Journal of Dermatology
  Publication of IADVL, WB
  Official organ of AADV
Indexed with Science Citation Index (E) , Web of Science and PubMed
Users online: 145  
Home About  Editorial Board  Current Issue Archives Online Early Coming Soon Guidelines Subscriptions  e-Alerts    Login  
    Small font sizeDefault font sizeIncrease font size Print this page Email this page

Table of Contents 
Year : 2011  |  Volume : 56  |  Issue : 4  |  Page : 444
Omalizumab in treatment-resistant chronic spontaneous urticaria

Skin Department, Shree Skin Centre, 22, L market, Sector 8, Nerul, Navi Mumbai, India

Date of Web Publication10-Sep-2011

Correspondence Address:
Kiran V Godse
Skin Department, Shree Skin Centre, 22, L market, Sector 8, Nerul, Navi Mumbai
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0019-5154.84737

Rights and Permissions

How to cite this article:
Godse KV. Omalizumab in treatment-resistant chronic spontaneous urticaria. Indian J Dermatol 2011;56:444

How to cite this URL:
Godse KV. Omalizumab in treatment-resistant chronic spontaneous urticaria. Indian J Dermatol [serial online] 2011 [cited 2022 Jan 23];56:444. Available from:


According to EAACI/GA 2 LEN/EDF/WAO guidelines, chronic spontaneous urticaria (CSU) is defined by the spontaneous occurrence of wheals and/or angioedema over more than 6 weeks. [1] GA 2 LEN task force report mentions that the detrimental effect of CSU on the quality of life is greater than that of most other skin diseases and similar to that of severe coronary artery disease. [2] Guideline mentions omalizumab as the fourth-line option in the treatment of CSU. [3] First-line options are non-sedating antihistamines in fourfold doses, and second-line options include leukotriene antagonist or changing non-sedating antihistamine. There are few reports of success of omalizumab in the treatment of CSU. [4],[5] Omalizumab, a recombinant, humanized, monoclonal antibody against immunoglobulin IgE, represents a unique therapeutic approach for the treatment of allergic diseases.

We treated five patients with treatment-resistant CSU with omalizumab. Dose of omalizumab was calculated according to body weight and serum IgE level. All patients had severe urticaria that required multiple antihistamines, steroids or dapsone to control symptoms. In spite of therapy, they had severe symptoms like urticaria, angioedema and itching. Patients were treated with omalizumab according to the dose schedule of asthma [Table 1]. Treatment study period was 4 months. Treatment response was assessed by urticaria activity score (UAS) and need of antihistamines or other therapies. The UAS was recorded by each patient daily and was obtained from the patients weekly. The number of wheals was scored from 0 to 3: 0, no wheals; 1, less than 20 wheals; 2, 20-50 wheals; 3, >50 wheals almost covered large confluent areas of wheals. Severity of itch was scored as 0, none; 1, mild; 2, moderate; and 3, severe. One has to add both these scores, viz., for both the number of wheals and the severity of itch, on a given day for each of the days in a given week to get the weekly UAS. The possible weekly aggregate UAS thereby ranged from 0 to 42. Daily average score ranged between 0 and 6.
Table 1: Clinical features of five CSU patients

Click here to view

There was significant improvement in all the patients, with reduction in UAS and need of antihistamines. At the end of 4 th month, two patients were free from symptoms and other three required antihistamine to control their symptoms. Side effects were recorded in two patients in the form of headache and fatigue.

Study from Germany reported that all nine patients who had severe therapy-resistant urticaria improved with omalizumab. [6] Physical urticaria patients have also shown overall excellent response to omalizumab in the study from Germany. [7]

This paper supports latest EAACI/GA 2 LEN/WAO/EDF guideline which mentions the use of omalizumab as a fourth-line treatment in CSU.

   References Top

1.Zuberbier T, Asero R, Bindslev-Jensen C, Walter Canonica G, Church MK, Gime´nez-Arnau A et al. EAACI/ GA 2 LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria. Allergy 2009;64:1417-26.  Back to cited text no. 1
2.Maurer M, Weller K, Bindslev-Jensen C, Giménez-Arnau A, Bousquet P, Bousquet J et al. Unmet clinical needs in chronic spontaneous urticaria. A GA 2 LEN task force report(1). Allergy 2011;66:317-30.  Back to cited text no. 2
3.Zuberbier T, Asero R, Bindslev-Jensen C, Walter Canonica G, Church MK, Gime´nez-Arnau A et al. EAACI/ GA 2 LEN/EDF/WAO guideline: Management of urticaria. Allergy 2009;64:1427-43.  Back to cited text no. 3
4.Kaplan AP, Joseph K, Maykut RJ, Geba GP, Zeldin RK. Treatment of chronic autoimmune urticaria with omalizumab. J Allergy Clin Immunol 2008;122:569-73.  Back to cited text no. 4
5.Godse KV. Omalizumab in severe chronic urticaria. Indian J Dermatol Venereol Leprol 2008;74:157-8.  Back to cited text no. 5
[PUBMED]  Medknow Journal  
6.Groffik A, Mitzel-Kaoukhov H, Magerl M, Maurer M, Staubach P. Omalizumab-An effective and safe treatment of therapy-resistant chronic spontaneous urticaria. Allergy 2011;66:303-5.  Back to cited text no. 6
7.Metz M, Altrichter S, Ardelean E, Kessler B, Krause K, Magerl M, et al. Anti-immunoglobulin E treatment of patients with recalcitrant physical urticaria. Int Arch Allergy Immunol 2011;154:177-80.  Back to cited text no. 7


  [Table 1]

This article has been cited by
1 Successful Treatment of the Different Urticaria Subtypes
Bettina Wedi
Current Dermatology Reports. 2015;
[Pubmed] | [DOI]
2 Wytyczne EAACI/GA2LEN/EDF/WAO dotyczace definicji, klasyfikacji, rozpoznawania i leczenia pokrzywki: weryfikacja z 2013 roku z poprawkami
T. Zuberbier,W. Aberer,R. Asero,C. Bindslev-Jensen,Z. Brzoza,G.W. Canonica,M.K. Church,L.F. Ensina,A. Giménez-Arnau,K. Godse,M. Gonçalo,C. Grattan,J. Hebert,M. Hide,A. Kaplan,A. Kapp,A.H. Abdul Latiff,P. Mathelier-Fusade,M. Metz,A. Nast,S.S. Saini,M. Sánchez-Borges,P. Schmid-Grendelmeier,F.E.R. Simons,P. Staubach,G. Sussman,E. Toubi,G.A. Vena,B. Wedi,X.J. Zhu,M. Maurer
Alergologia Polska - Polish Journal of Allergology. 2015;
[Pubmed] | [DOI]
3 The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria
Tse Wen Chang,Christina Chen,Chien-Jen Lin,Martin Metz,Martin K. Church,Marcus Maurer
Journal of Allergy and Clinical Immunology. 2014;
[Pubmed] | [DOI]
4 The EAACI/GA2LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update
T. Zuberbier,W. Aberer,R. Asero,C. Bindslev-Jensen,Z. Brzoza,G. W. Canonica,M. K. Church,L. F. Ensina,A. Giménez-Arnau,K. Godse,M. Gonçalo,C. Grattan,J. Hebert,M. Hide,A. Kaplan,A. Kapp,A. H. Abdul Latiff,P. Mathelier-Fusade,M. Metz,A. Nast,S. S. Saini,M. Sánchez-Borges,P. Schmid-Grendelmeier,F. E. R. Simons,P. Staubach,G. Sussman,E. Toubi,G. A. Vena,B. Wedi,X. J. Zhu,M. Maurer
Allergy. 2014; : n/a
[Pubmed] | [DOI]
5 Omalizumab in the Treatment of Chronic Urticaria
L. Francés,M. Leiva-Salinas,J.F. Silvestre
Actas Dermo-Sifiliográficas (English Edition). 2014;
[Pubmed] | [DOI]
6 Omalizumab en el tratamiento de la urticaria crónica
L. Francés,M. Leiva-Salinas,J.F. Silvestre
Actas Dermo-Sifiliográficas. 2013;
[Pubmed] | [DOI]
7 Omalizumab for chronic urticaria: A case series and overview of the literature
Ivyanskiy, I., Sand, C., Thomsen, S.F.
Case Reports in Dermatology. 2012; 4(1): 19-26
8 Omalizumab in chronic urticaria
Metz, M., Maurer, M.
Current Opinion in Allergy and Clinical Immunology. 2012; 12(4): 406-411


Print this article  Email this article
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Article in PDF (341 KB)
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
* Registration required (free)  

    Article Tables

 Article Access Statistics
    PDF Downloaded98    
    Comments [Add]    
    Cited by others 8    

Recommend this journal